Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 vaccine for pediatric high-grade glioma and ependymoma
NCT02722512Phase 1Terminated
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Jul 2016
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of vitespen in glioblastoma multiforme (GBM), astrocytoma, anaplastic ependymoma and 2 more, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Started Jul 2016; status: terminated.
02
Drugs
vitespen
03
Conditions
glioblastoma multiforme (GBM)astrocytomaanaplastic ependymomaclear cell ependymoma (CCE)ependymoma
Beyond the preview
Go deeper on NCT02722512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722512.